285 related articles for article (PubMed ID: 28151712)
1. Integration of Novel Agents into the Care of Patients with Multiple Myeloma.
Orlowski RZ; Lonial S
Clin Cancer Res; 2016 Nov; 22(22):5443-5452. PubMed ID: 28151712
[TBL] [Abstract][Full Text] [Related]
2. Progress and Paradigms in Multiple Myeloma.
Anderson KC
Clin Cancer Res; 2016 Nov; 22(22):5419-5427. PubMed ID: 28151709
[TBL] [Abstract][Full Text] [Related]
3. Which therapies will move to the front line for multiple myeloma?
Cejalvo MJ; de la Rubia J
Expert Rev Hematol; 2017 May; 10(5):383-392. PubMed ID: 28388244
[TBL] [Abstract][Full Text] [Related]
4. The role of ixazomib as an augmented conditioning therapy in salvage autologous stem cell transplant (ASCT) and as a post-ASCT consolidation and maintenance strategy in patients with relapsed multiple myeloma (ACCoRd [UK-MRA Myeloma XII] trial): study protocol for a Phase III randomised controlled trial.
Striha A; Ashcroft AJ; Hockaday A; Cairns DA; Boardman K; Jacques G; Williams C; Snowden JA; Garg M; Cavenagh J; Yong K; Drayson MT; Owen R; Cook M; Cook G
Trials; 2018 Mar; 19(1):169. PubMed ID: 29514706
[TBL] [Abstract][Full Text] [Related]
5. Thalidomide in the treatment of multiple myeloma.
Kastritis E; Dimopoulos MA
Best Pract Res Clin Haematol; 2007 Dec; 20(4):681-99. PubMed ID: 18070713
[TBL] [Abstract][Full Text] [Related]
6. Novel agents for multiple myeloma to overcome resistance in phase III clinical trials.
Orlowski RZ
Semin Oncol; 2013 Oct; 40(5):634-51. PubMed ID: 24135408
[TBL] [Abstract][Full Text] [Related]
7. Treatment of relapsed and refractory multiple myeloma in the era of novel agents.
van de Donk NW; Lokhorst HM; Dimopoulos M; Cavo M; Morgan G; Einsele H; Kropff M; Schey S; Avet-Loiseau H; Ludwig H; Goldschmidt H; Sonneveld P; Johnsen HE; Bladé J; San-Miguel JF; Palumbo A
Cancer Treat Rev; 2011 Jun; 37(4):266-83. PubMed ID: 20863623
[TBL] [Abstract][Full Text] [Related]
8. Multiple drug combinations of bortezomib, lenalidomide, and thalidomide for first-line treatment in adults with transplant-ineligible multiple myeloma: a network meta-analysis.
Piechotta V; Jakob T; Langer P; Monsef I; Scheid C; Estcourt LJ; Ocheni S; Theurich S; Kuhr K; Scheckel B; Adams A; Skoetz N
Cochrane Database Syst Rev; 2019 Nov; 2019(11):. PubMed ID: 31765002
[TBL] [Abstract][Full Text] [Related]
9. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
10. Design and rationale of FOCUS (PX-171-011): a randomized, open-label, phase 3 study of carfilzomib versus best supportive care regimen in patients with relapsed and refractory multiple myeloma (R/R MM).
Hájek R; Bryce R; Ro S; Klencke B; Ludwig H
BMC Cancer; 2012 Sep; 12():415. PubMed ID: 22992303
[TBL] [Abstract][Full Text] [Related]
11. The future of Cochrane Neonatal.
Soll RF; Ovelman C; McGuire W
Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
[TBL] [Abstract][Full Text] [Related]
12. New Developments in Diagnosis, Prognosis, and Assessment of Response in Multiple Myeloma.
Landgren O; Rajkumar SV
Clin Cancer Res; 2016 Nov; 22(22):5428-5433. PubMed ID: 28151710
[TBL] [Abstract][Full Text] [Related]
13. Novel targets and derived small molecule inhibitors in multiple myeloma.
Podar K
Curr Cancer Drug Targets; 2012 Sep; 12(7):797-813. PubMed ID: 22671928
[TBL] [Abstract][Full Text] [Related]
14. Carfilzomib and pomalidomide: recent advances in the treatment of multiple myeloma.
Highsmith KN; Chen SE; Horowitz S
Pharmacotherapy; 2014 Sep; 34(9):927-40. PubMed ID: 25044413
[TBL] [Abstract][Full Text] [Related]
15. Immune Therapies in Multiple Myeloma.
Kumar SK; Anderson KC
Clin Cancer Res; 2016 Nov; 22(22):5453-5460. PubMed ID: 28151713
[TBL] [Abstract][Full Text] [Related]
16. Management strategies for relapsed/refractory multiple myeloma: current clinical perspectives.
Jakubowiak A
Semin Hematol; 2012 Jul; 49 Suppl 1():S16-32. PubMed ID: 22727389
[TBL] [Abstract][Full Text] [Related]
17. Multiple myeloma: Updates for pharmacists in the treatment of relapsed and refractory disease.
Ashjian E; Redic K
J Oncol Pharm Pract; 2016 Apr; 22(2):289-302. PubMed ID: 25694345
[TBL] [Abstract][Full Text] [Related]
18. Current therapeutic strategies for multiple myeloma.
Torimoto Y; Shindo M; Ikuta K; Kohgo Y
Int J Clin Oncol; 2015 Jun; 20(3):423-30. PubMed ID: 25855312
[TBL] [Abstract][Full Text] [Related]
19. New horizons in multiple myeloma therapy.
Santos ES; Kharfan-Dabaja MA
Expert Rev Anticancer Ther; 2006 Oct; 6(10):1483-501. PubMed ID: 17069532
[TBL] [Abstract][Full Text] [Related]
20. [Multiple myeloma].
Abe M; Miki H; Nakamura S
Rinsho Ketsueki; 2016 Mar; 57(3):260-9. PubMed ID: 27076236
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
